All News

Systematic review of CV outcomes w/ SGLT2 inhibitors- 5 studies, 11,190 IMID pts (SSc 25%, SLE 71%) SGLT2i use assoc w/ signif lower all-cause mortality and heart failure risk (no clear MI benefit). SGLT2i have establ use in NIDDM, CHF & CKD Pts. https://t.co/U28aBsQpJ8 https://t.co/g9Ak2MCJEN

https://buff.ly/S1ss5wm

Rheumatoid Factor as a Potential Marker of Cardiometabolic and Hepatic Risk. RF has been assoc w/ ASHD, MI, CAD, ischemic stroke, obesity, insulin resistance, type 2 diabetes, and metabolic syndrome -- all mediated via downstream inflammation. https://t.co/gQvqMJmyPw https://t.co/TmoodnuJTe

Rheumatoid Factor Beyond Rheumatoid Arthritis: A Potential Marker of Cardiometa…

Review of GLP-1 Receptor Agonists in Psoriasis Psoriasis is a chronic immune-mediated inflammatory disease plaqued by systemic comorbidities that increase morbidity, mortality, and treatment complexity. Obesity is a significant contributor to psoriatic disease. https://t.co/R1Uutdjcvz

New Dyslipidemia (Cholesterol) Guidelines from AHA/ACC: A) Check during childhood; B) Lower Targets: if 10-year ASCVD risk =10%, aim for LDL <70; if you have ASCVD/MI/CV, aim for 55; C) chk lipoprotein(a) once; D) supplements dont lower cholesterol - statins do. https://t.co/tRwdg6GHm8

A deep dive into Lupus 🔬 Abstract 2601: Single-cell insights in SLE & pre-clinical autoimmunity 🔹 Plasmablast expansion → high disease activity & SLE risk 🔹 Metabolic activity varies by cell type 🔹 Established disease: ↑ glycolysis & OxPHOS changes @RheumNow #ACR25

This retrospective study evaluated incidence of MACE & mortality among PsA pts on GLP-1RAs vs non-GLP-1RAs After propensity score matching, pts on GLP-1RAs = ⬇️ risk of developing MACE & ⬇️ mortality vs. non GLP-1RAs Interesting data, More research reqd #ACR25 @RheumNow Abs0849 https://t.co/hiPpQH0K3O

TriNetX database 4000+ pts PsA + GLP-1 RA & 86000+ PsA non GLP-1 ctrls Without much surprise GLP-1 treated pts had lower risk of MACE and death Observational, retrospective study. Now awaiting the prospective evidence. RCT on the way but capturing MACE and death are always https://t.co/GWbAMC1mJK

https://x.com/AurelieRheumo/status/1982803333078225298/photo/1

This morning in the plenary, same theme, but in PsA: Similar metabolic/CV concerns Similarly benefit from GLP-1 RA looking at TriNetX data again, reduced MACE Now prospective trials in rheum disease, for both metabolic benefits & disease activity? #ACR25 ABST0849 @RheumNow https://t.co/DHZN1hwbIG

https://x.com/drdavidliew/status/1982796177725591741/photo/1

GLP-1 RA meds: we are just starting to see their impact in rheumatoid arthritis. We know metabolic, CV risk in RA, but what to do? RA pts in TriNetX, obese non-diabetic GLP-1 RA reduced 1y CV events & also all-cause mortality Soon will be near-standard #ACR25 ABST0445 @RheumNow https://t.co/4ptAHdmf9q

https://x.com/drdavidliew/status/1982794776119226821/photo/1

SGLT-2 inhibitors and the prevention of autoimmune rheumatic disease SGLT-2 inhibitors offer benefits beyond glycemic control, such as cardioprotective and nephroprotective effects, and modest weight loss. A recent study also suggests they may have immunomodulatory effects and https://t.co/grsgHFQic5

New ideas in gout management Gout flares are associated with cardiovascular events. Treating gout to target serum urate level prevents flares, but whether such treatment can also prevent cardiovascular events is unknown. https://t.co/C8G39JzP9Y https://t.co/NAClL0JLGX

New ideas in gout management | RheumNow

#EULAR2025 Abstr#OP0035 SGLT2-i and GLP-1 agonist are increasingly used to treat diabetes. Population based study in Canada showed no significant difference in risk of developing an autoimmune rheumatic disease with GLP-1-RA or SGLT2i relative to DPP4i treatment @RheumNow https://t.co/CvPcOqehtl

https://x.com/Yuz6Yusof/status/1932939395834818772/photo/1

3-year, RCT of Mediteranean diet vs usual care in 924 older adults w/ metabolic syndrome & BMI > 27. Med. diet shows signif wt loss (3.4% vs 0.4%), w/ improved BMD (by DEXA) at year 3, especially in women. https://t.co/mllx6l1QnM https://t.co/I5e8PXX2oX

Mediterranean Diet, Physical Activity, and Bone Health in Older Adults

GLP-1 agonists effective in Rxing MASH - metabolic dysfunction-assoc steatohepatitis (AKA NAFLD, NASH). DBRPCT w/ 1100 pts (mean BMI 34-35). A good perspective article from Sensible Medicine. https://t.co/NeaX5qcnPA https://t.co/5DHlKfH105 https://t.co/sCfvcm7g54

Metformin Effective in Osteoarthritis The diabetes drug metformin provided overweight/obese patients with osteoarthritis (OA) of the knee with significantly greater pain relief than did placebo in a small randomized trial, researchers said. https://t.co/7krvFFfRFC https://t.co/g1UyNjazUv

Metformin Effective in Osteoarthritis | RheumNow

Metformin Effective in Osteoarthritis | RheumNow

CRP and Hidradenitis Supprativa A post hoc analysis of 2 phase 3 randomized clinical trials (PIONEER I and II) of adalimumab vs Placebo in patients with active Hidradenitis suppurativa (HS) demonstrated more severe HS that was associated with elevated CRP had a higher BMI.… https://t.co/VxFRjt3cRw https://t.co/rdNIvzMaP8

Full read, comprehensive review of Hidradenitis Supprativa in Lancet Feb 1, 2025 Common assn; DM, IBD, Smoking, Obesity, metabolic syndr, NASH, SpA, RA FDA approved Rx: Adalimumab, Secukinumab, Bimekizumab https://t.co/9er7TkNXpK https://t.co/N6sal9URv3

Hidradenitis suppurativa

SLE pts have increased risk of atherosclerotic cardiovascular disease (ASCVD). Systemic inflammation & glucocorticoid exposure are significant drivers of ASCVD in SLE. Screening recommended - Framingham Risk Score, ACC/AHA risk score & others reviewed https://t.co/jJHNJOU606 https://t.co/JJxiBczMwi

Atherosclerotic Cardiovascular Disease Risk Prediction in Systemic Lupus Erythe…

GLP-1 Agonists Alleviate Knee Osteoarthritis In October, the NEJM published a randomized clinical trial demonstrating the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1ra) in patients with obesity and knee osteoarthritis. https://t.co/jlYGDTTsYZ https://t.co/O23mN1CPVO

GLP-1 Agonists Alleviate Knee Osteoarthritis | RheumNow

Topics

All News

Do you get our email newsletter?